Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Next Previous
Search
Drug Profile

Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Alternative Names: AMF-1c-120; Anti-PrP antibodies - Amorfix; DSE3 ab120; DSE3 ab120/urease

Latest Information Update: 18 Dec 2014

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amorfix Life Sciences
  • Developer Helix BioPharma; ProMIS Neurosciences
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Polyribitol phosphate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Ovarian cancer

Most Recent Events

  • 08 Aug 2014 Suspended - Preclinical for Ovarian cancer in Canada (Parenteral)
  • 09 Apr 2013 Pharmacodynamics data from a preclinical study in Ovarian cancer released by Amorfix
  • 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012. http://www.amorfix.com

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top